2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)

NCT ID: NCT03281837

Last Updated: 2020-07-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 148 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-10-01
• Study Completion Date: 2020-07-16

Brief Summary

Knee osteoarthritis (OA) is among the most common causes of musculoskeletal pain and disability. At present, there is no cure for OA. Therefore, the primary aims of therapy are to reduce pain, maintain or improve function and mobility, and prevent or slow the progression of adverse changes to the joint tissues, while keeping potential therapeutic toxicities to a minimum. Current treatment guidelines begin with non-pharmacologic modalities, such as patient education, weight loss, and physical therapy. Several exercise-based therapeutic approaches, such as aerobic exercise programs, range-of-motion exercises, and muscle-strengthening exercises are recommended and have shown clinical benefit in randomized, controlled clinical trials. However, non-pharmacologic approaches frequently provide insufficient pain relief and restoration of function and mobility, and pharmacologic modalities become necessary. Although simple analgesics such as acetaminophen provide relief for many OA subjects with mild to moderate pain, alternatives should be considered for subjects who fail to obtain adequate symptomatic relief with these measures.

This post-market, single blind, multicenter, randomized, controlled clinical study is designed to enroll a relatively young, active population of subjects with patellofemoral osteoarthritis (PFOA) and/or tibiofemoral osteoarthritis (TFOA), and to compare responses to treatment with 2 weekly intra-articular (IA) hyaluronan (HA) injections, with each injection given 1 week apart, of HYMOVIS combined with a physical exercise program (PEP) to PEP alone. Because PEP or exercise programs may be considered the first line standard of care in OA knee pain, particularly in younger, active patients, the hypothesis of the study is that Hymovis combined with PEP program provides greater relief of pain associated with knee OA in the enrolled study subjects than with use of PEP alone.

The study provides for subjects randomized to the PEP alone study group to cross over to HYMOVIS+PEP if improvement has not been achieved by the 3 month follow up visit.

Subjects will be recruited over an 18 month period. The duration of the trial per center will be approximately 27 months. This includes the enrollment period of 6 months, the follow-up period at 3 and 6 months and the additional follow-up period for patients who crossed-over; they will be followed for an additional 6 months following the initial 3month follow-up. The trial will end when the last subject makes the last visit.

Conditions

Osteoarthritis, Knee; Knee Osteoarthritis; Patellofemoral Osteoarthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Group 1: Hymovis plus Physical Exercise Program (PEP)

Intra-articular (IA) Hyaluronan (HA) (Hymovis 24mg/3mL) combined with Physical Exercise program (PEP)

Group Type: EXPERIMENTAL

HYMOVIS plus Physical Exercise Program (PEP)

Intervention Type: DEVICE

1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)

Group 2: Physical Exercise Program (PEP) alone alone

Specified designed Physical Exercise Program (PEP) not combined with any other intervention

Group Type: OTHER

Physical Exercise Program (PEP) alone

Intervention Type: OTHER

Physical Exercise Program (PEP) alone for at least 8 weeks

Group 3: Cross-Over group

Patients who were randomized to receive only Physical Exercise Program (PEP) alone and do not respond after 3 months to this intervention will have the opportunity to cross-over to receive 2 intra-articular weekly injections, each injection given 1 week apart, of Hymovis.

Group Type: OTHER

HYMOVIS plus Physical Exercise Program (PEP)

Intervention Type: DEVICE

1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)

Interventions

HYMOVIS plus Physical Exercise Program (PEP)

1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)

Intervention Type: DEVICE

Physical Exercise Program (PEP) alone

Physical Exercise Program (PEP) alone for at least 8 weeks

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Male or female ≥21 years and ≤60 years old and with BMI ≤40
• Moderate to severe knee OA pain ≥3 and ≤8 on the NRS pain subscale in the affected knee (signal knee)
• Mild or no pain ≤3 on the numeric rating scale (NRS) pain subscale in the contralateral knee (unaffected knee)
• Persistent knee pain lasting at least 3 months prior to Screening
• Active life-style (play or train themselves at least 2 to 3 times per week)
• Diagnosis of knee OA confirmed by radiographic assessment (must be performed within 6 months prior to screening visit):

1. anterior-posterior view (weight bearing extension or semi-flexion) of tibiofemoral joint, (posterior-anterior/Rosenberg view as an additional alternate)

2. lateral view of both the tibiofemoral and patellofemoral joints

3. Merchant X-ray (or Sunrise) view for patellofemoral joint.

• Radiographic assessment must confirm K-L Grade 1 to 3 for TFOA and/or K-L Grade 1 to for PFOA.
• Radiographic assessment confirms normal articulation of patella and trochlea in Merchant (or Sunrise) view

Exclusion Criteria

• Radiographic assessment confirms abnormal patellofemoral tracking or articulation in lateral and/or Merchant view (or Sunrise View)
• Major injury to or disorder of the contralateral knee or other weight-bearing joint that would interfere with the study assessments.
• Secondary OA of the study joint due to a prior or concomitant condition (e.g., septic arthritis, inflammatory joint disease, gout, articular fracture, major dysplasia, or congenital abnormality, hemochromatosis, etc.).
• Surgery to the study joint within the previous 12 months prior to Screening. Surgery to the contralateral knee or other weight-bearing joint within the previous 12 months that would interfere with the study assessments.
• Patients with either total joint replacement implants, unicondylar implants or patellofemoral replacement implants in the affected joint.
• Ligament reconstruction of the affected knee within 3 years.
• Inflammatory arthropathies such as rheumatoid arthritis, lupus, or psoriatic arthritis.
• Episode of gout or calcium pyrophosphate (pseudogout) diseases within 6 months prior to Screening.
• IA or local peri-articular corticosteroid injections to the study joint/knee within 8 weeks (2 months) prior to Screening or to any other joint (other than the study joint) or soft tissue area within 1 month prior to Screening.
• Any oral corticosteroid within 1 month prior to Screening. Steroid inhalants are permitted if the Subject has been on a stable regimen for the past 1 month prior to Screening and remains on this regimen throughout the course of the trial.
• Intra-articular HA in the study joint within 6 months prior to Screening.
• History of allergic reaction to an intra-articular Hyaluronic acid injection.
• Known hypersensitivity (allergy) to gram positive bacterial proteins.
• Use of glucosamine or chondroitin sulfate containing products unless the subject is on stable doses for at least 14 days prior to Screening and willing to remain on these stable doses throughout the course of the study.
• Inability to perform the climbing stair test.
• X-ray findings of acute fractures, severe loss of bone density, avascular necrosis and/or severe deformity.
• Axial deviation of the lower limbs greater than 20 degrees in valgus or varus on standing X-ray.
• Symptomatic OA of either hip or spine with a pain score ≥2 on the NRS on or off pain medication.
• Clinically significant medio-lateral and/or anterior-posterior instability.
• Osteonecrosis of either knee.
• Participation in a physical therapy regimen that has not been stable during the 1 month prior to Screening and the subject is unwilling or unable to maintain the same regimen throughout the course of the trial or is unwilling to stop previously prescribed or self-initiated physical therapy regimen and switch solely to and initiate study defined PEP program.
• K-L Grade 4 TFOA of the knee (i.e., large osteophytes, marked narrowing, severe sclerosis, and definite deformity).
• K-L Grade 4 PFOA of the knee (i.e., large osteophytes, marked narrowing, severe sclerosis, definite deformity)
• Hemiparesis of the lower limbs.
• Significant surgery of lower limbs (hip, ankle, foot) that may interfere with knee assessments.
• Chronic use of analgesia for pain (including pain in the other knee or any other joint) that may interfere with the evaluations of the test knee (such as possible use of rescue medication for these other conditions).
• Known allergies to acetaminophen and hyaluronan preparations.
• Know hypersensitivity (allergy) to anesthetics
• Recurrent medical history of severe allergic or immune-mediated reactions.
• Active infection or skin diseases in the area of the potential injection site or joint.
• Any dermatological disease overlying the signal joint that would contraindicate multiple injections or aspirations.
• Use of any agent reported to have symptom relief for arthritis or be a disease/structure modifying drug (e.g. doxycycline, long-term tetracycline, s-adenosylmethionine [SAM], methylsulfonylmethane [MSM] or dimethylsulfoxide [DMSO], dietary supplements or any herbal remedy taken for arthritic and joint conditions within the past month (exceptions as specified in Exclusion #14).
• Peripheral neuropathy that would be severe enough to interfere with the evaluation of the subject.
• Psychological status (e.g., anxiety, depression, poor sleep quality, pain catastrophizing, etc.) that may interfere with functional assessment of the target knee.
• Vascular insufficiency of lower limbs that is severe enough to interfere with the evaluation of the subject.
• Concomitant therapy with anticoagulants (low dose aspirin, not exceeding 325 mg per day as an anti-thrombotic agent is permitted if stable for 1 month prior to Screening and remains stable throughout the study).
• Any concomitant disease(s) or condition(s) that may interfere with the free use and evaluation of the affected knee for the 6 months course of the trial (cancer, other rheumatic diseases, gout, severe congenital defects, etc.).
• Any serious mobility problems (e.g. Parkinson's disease) or claustrophobia
• Any concomitant chronic disease(s) or condition(s) that may predispose them to a high probability of interfering with the completion of the 6-month follow-up of the study such as peptic ulcer, liver disease, severe coronary disease, renal disease, cancer, pregnancy, alcoholism, drug abuse, mental state, or other clinically significant condition.
• Excessive alcohol consumption or alcoholism that would be contraindicated with the use of acetaminophen.
• Use of marijuana, whether prescribed or not
• Any clinically significant diagnostic test and/or abnormal laboratory test result(s) that, in the opinion of the clinical investigator, may place the subject's health at risk, impact the study, or impact the subject's ability to complete the study.
• Inability to legally comprehend the details and nature of the study for any reason, including psychiatric illness.
• Likelihood of protocol violations or unlikely to compete the study for any reason, as determined by the clinical investigator.
• Continued participation in an experimental drug/device study or any clinical trial within the previous 8 weeks prior to Screening. Subjects must have fully completed participation in an experimental drug/device study of any clinical trial at least 8 weeks prior to screening.
• Pregnancy, breastfeeding, planned conception, premenopausal women who have not had tubal ligation, hysterectomy, or are unwilling or unable to utilize contraceptive measures (or contraception)
• Prior history of any malignancy with the exception of basal cell carcinoma of the skin treated more than 2 years prior to Screening.
• Significant bleeding diathesis.
• Participation in current litigation for injuries related to the study knee or other injuries that might interfere with their completion of the study protocol.
• Non-English speaking subjects.

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fidia Pharma USA Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Cedars-Sinai Medical Center

Role: PRINCIPAL_INVESTIGATOR

Cedars-Sinai Medical Center - Department of Orthopaedic Surgery

Kerlan-Jobe Orthopaedic Clinic

Role: PRINCIPAL_INVESTIGATOR

Kerlan-Jobe Orthopaedic Clinic

Locations

Tucson Orthopaedic Institute Research Center

Tucson, Arizona, United States

CORE Orthopaedic Medical Center

Encinitas, California, United States

Kerlan-Jobe Orthopaedic Clinic

Los Angeles, California, United States

Cedars-Sinai Medical Center

Los Angeles, California, United States

Horizon Clinical Research / Grossmont Orthopaedic Medical Group

San Diego, California, United States

Andrews Institute Orthopaedics and Sports Medicine - Andrews Research & Education Foundation

Gulf Breeze, Florida, United States

Cartilage Research Foundation, Inc. - OrthoIndy

Greenwood, Indiana, United States

New York University - Center for Musculoskeletal Care

New York, New York, United States

Hospital for Special Surgery

New York, New York, United States

IntegraTrials LLC / OrthoVirginia

Arlington, Virginia, United States

Countries

United States

Other Identifiers

EQE7-16-01

Identifier Type: -

Identifier Source: org_study_id